Slide 1: Letter to stock exchanges: Investor/Analysts Presentation
P¥ AUROBINDO November 11, 2020 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), Phiroz Jeejeebhoy Towers, MUMBAI ·400 051 25th floor, Dalal Street, MUMBAI ·400 001 Company Code No. AURO
Slide 2: Aurobindo Pharma Ltd Earnings Presentation November 2020
AUROBINDO PHARMA LTD Earnings Presentation November 2020
Slide 3: Disclaimer
Disclaimer This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of Aurobindo Pharma, nor shall it, or any part hereof
Slide 4: Index
Index Q2FY21 Business & Financial Highlights 01 Financial Performance 02 Filing Snapshot 03 R&D – Speciality pipeline under development 04
Slide 5: Q2FY21 Business & Financial Highlights
1 Q2FY21 Business & Financial Highlights
Slide 6: Consolidated Financial Performance – Q2 FY21
Consolidated Financial Performance – Q2 FY21 In Rs Cr Revenue EBITDA Profit After Tax 15.8% YoY 22.7% YoY 26.0% YoY 9.4% QoQ 14.0% QoQ 3.3% QoQ 20.8% 21.2% 22.1% EBITDA Margin
Slide 7: Consolidated Financial & Business Highlights – Q2 FY21
Consolidated Financial & Business Highlights – Q2 FY21 Revenue from operations at Rs. 6,483.4 crore, witnessed a growth of 15.8% YoY EBIDTA before Forex and Other income at Rs. 1,432.8 crore, an increase of 22.7% YoY; EBITDA margin is at 22.1% Net Profit after JV share, minority interest at Rs. 806.
Slide 8: Consistent Quarterly Performance
Consistent Quarterly Performance Revenue (Rs Cr) US Revenue ($ Mn) EBITDA (Rs Cr) Net Debt ($ Mn) - Reported & Without Acquisitions
Slide 9: US Business Performance Highlights
US Business Performance Highlights Revenue (Rs Cr) Revenue Mix H1FY21 Total Injectables 19.6%% 6.2% US Formulations • US revenue in Q2FY21 witnessed a growth of 12.5% YoY to Rs 3,189.8 crore, accounting 49.2% of consolidated revenue. On constant currency basis, revenue grew by 6.6% YoY to US$ 430 mi
Slide 10: Europe, ARV, Growth Markets, API Business Performance Highlights
Europe, ARV, Growth Markets, API Business Performance Highlights Europe Revenues Growth Markets Revenues ARV Revenues API Revenues • Europe revenue in Q2FY21 increased by 8.1% • Revenue from Growth markets formulations in Q2FY21 increased by • ARV business revenue for Q2FY21 • In Q2FY21, API busines
Slide 11: Financial Performance
{ 2] AUROBINDO Financial Performance
Slide 12: Consolidated Financial Performance
Consolidated Financial Performance Rs Cr Q2FY21 Q2FY20 (%) Chg Q1FY21 (%) Chg Revenue from operations 6,483.4 5,600.5 15.8 5,924.8 9.4 Gross Profit 3,967.7 3,232.2 22.8 3,517.4 12.8 Gross Margin 61.2% 57.7% 59.4% Overheads 2,534.9 2,064.7 22.8 2,260.0 12.2 EBITDA (before forex and other income) 1,43
Slide 13: Financial Performance – 5 Year trend
Financial Performance – 5 Year trend Rs. Cr FY16 FY17 FY18 FY19 FY20 Revenue 13,955 15,090 16,500 19,564 23,099 Gross Profit 7,793 8,656 9,747 10,851 13,363 Gross Profit Margin 55.8% 57.4% 59.1% 55.5% 57.9% EBITDA 3,188 3,434 3,789 3,952 4,864 EBITDA Margin 22.8% 22.8% 23.0% 20.2% 21.1% Net Profit 2
Slide 14: Debt Profile
Debt Profile Fx Loan US$ Mn Debt as on (Rs Crore) Mar-18 Mar-19 Mar-20 June-20 Sep-20 Closing Rate1 US$ = INR 65.17 69.155 75.6650 75.5050 73.770 731 1,006 733 633 663 Fx Loan restated in INR 4,766.9 6,959.0 5,549.2 4,776.0 4,888.1 Rupee Loan 4.1 8.1 16.9 0.6 100 Gross Debt 4,771.0 6,967.1 5,566.1 4
Slide 15: Filing Status
r 2 J AUROBIN DO alihter lif Filing Status
Slide 16: US Filings Snapshot as on 30th Sep 2020
US Filings Snapshot as on 30th Sep 2020 ANDA Filings Addressable Therapy ANDAs Market Size (US$ Bn) Non - Injectables CNS 106 23.2 Injectables CVS 94 29.7 ARV** 41 3.8 Gastroenterological 35 3.3 SSP & Cephs 31 0.6 Oncology & 41 14.1 Hormones Anti Diabetic 22 19.7 Unit wise ANDA Filings Controlled 15
Slide 17: Filing details
Filing details As at As at As at As at As at As at As at As at Jun As at Sep Category Approvals Mar 15 Mar 16 Mar 17 Mar 18 Mar 19 June 19 Mar 20 20 20 Formulations US* 376 398 429 478 541 551 586 604 629 449 (FA: 421, TA:28) 2,635 Dossiers (295 Europe** 1,756 2,224 2,521 2,848 3,003 3,082 3,214 3,2
Slide 18: R&D – Speciality pipeline under development
4 R&D – Speciality pipeline under development
Slide 19: Focus on Building a Diverse and Robust Specialty Products Portfolio
Focus on Building a Diverse and Robust Specialty Products Portfolio Biosimilars Inhalers Oncology & Hormones Topicals Transdermal Patches Nasals Depot Injections Vaccines
Slide 20: Specialty Products Portfolio - Biologics
Focus on Building a Diverse and Robust Specialty Products Portfolio - Biologics • Our Biologics Division is a fully integrated company (CuraTeQ Biologics Pvt Ltd) focused on developing and manufacturing high quality biosimilars • We are developing thirteen biosimilars in two phases (first and second
Slide 21: Specialty Products Portfolio: Topicals, Patches, Inhalers, Nasals
Focus on Building a Diverse and Robust Specialty Products Portfolio Topicals Transdermal Patches Inhalers Nasals Number of Products 37 8 8 6 Addressable Market Size $4.4 Bn $3.2 Bn $10.0 Bn $1.3 Bn Filing Status ANDAs*: 3 To start from FY21 To start from FY21 ANDAs*: 2 To file 3-4 products in Filing
Slide 22: Specialty Products Portfolio: Oncology, Depot Injection, Vaccines
Focus on Building a Diverse and Robust Specialty Products Portfolio Oncology & Hormones Depot Injection Vaccines Number of Products 84 3 5 Addressable Market Size $41.1 Bn $3.3 Bn $6.2 Bn^ Filing Status ANDAs*: Oncology- 30 To start from FY22 To start from FY22 & Hormones- 10 Filing Target To file a
Slide 23: Thank You
Thank You Investors Contact Investor Relations team ir@aurobindo.com 040-66725401